30 years of historical data (1996–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Alkermes plc trades at 21.0x earnings, 37% above its 5-year average of 15.3x, sitting at the 71st percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 11%. On a free-cash-flow basis, the stock trades at 9571.4x P/FCF, 319% above the 5-year average of 2285.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.0B | $4.7B | $4.9B | $4.7B | $4.3B | $3.7B | $3.2B | $3.2B | $4.6B | $8.4B | $8.4B |
| Enterprise Value | $4.5B | $4.2B | $4.7B | $4.6B | $4.4B | $3.8B | $3.3B | $3.3B | $4.6B | $8.5B | $8.5B |
| P/E Ratio → | 21.05 | 19.57 | 13.25 | 13.21 | — | — | — | — | — | — | — |
| P/S Ratio | 3.38 | 3.20 | 3.12 | 2.83 | 3.85 | 3.19 | 3.05 | 2.74 | 4.18 | 9.29 | 11.29 |
| P/B Ratio | 2.79 | 2.60 | 3.32 | 3.91 | 4.10 | 3.36 | 2.97 | 2.95 | 3.91 | 6.98 | 6.96 |
| P/FCF | 9571.39 | 9065.74 | 12.00 | 13.33 | — | 51.50 | 77.99 | — | 153.35 | — | — |
| P/OCF | 9571.39 | 9065.74 | 11.08 | 11.73 | 203.32 | 36.80 | 38.24 | 44.45 | 46.11 | 437.54 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Alkermes plc's enterprise value stands at 15.9x EBITDA, 32% below its 5-year average of 23.4x. The Healthcare sector median is 13.8x, placing the stock at a 15% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.85 | 2.99 | 2.78 | 3.93 | 3.26 | 3.18 | 2.81 | 4.19 | 9.39 | 11.42 |
| EV / EBITDA | 15.89 | 14.95 | 10.35 | 9.45 | 60.82 | 21.67 | — | — | 1012.78 | — | — |
| EV / EBIT | 17.59 | 16.55 | 9.97 | 10.40 | — | 38.63 | — | — | — | — | — |
| EV / FCF | — | 8070.42 | 11.46 | 13.09 | — | 52.58 | 81.37 | — | 153.77 | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Alkermes plc earns an operating margin of 17.2%. Operating margins have compressed from 24.9% to 17.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 14.7% is modest. ROIC of 14.9% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.3% | 86.3% | 84.2% | 84.8% | 80.4% | 83.2% | 82.8% | 84.6% | 83.9% | 82.9% | 82.3% |
| Operating Margin | 17.2% | 17.2% | 27.0% | 24.9% | -0.5% | 8.3% | -10.8% | -15.0% | -9.1% | -16.4% | -28.0% |
| Net Profit Margin | 16.4% | 16.4% | 23.6% | 21.4% | -14.2% | -4.1% | -10.7% | -16.8% | -12.7% | -17.5% | -28.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 14.7% | 14.7% | 27.5% | 31.7% | -14.7% | -4.4% | -10.3% | -17.4% | -11.7% | -13.1% | -16.5% |
| ROA | 10.6% | 10.6% | 17.5% | 17.4% | -7.9% | -2.4% | -5.9% | -10.8% | -7.7% | -9.0% | -11.6% |
| ROIC | 14.9% | 14.9% | 26.7% | 27.6% | -0.4% | 6.1% | -7.1% | -11.2% | -6.0% | -8.5% | -11.2% |
| ROCE | 14.4% | 14.4% | 26.2% | 26.9% | -0.4% | 6.4% | -7.7% | -12.1% | -6.6% | -9.8% | -13.3% |
Solvency and debt-coverage ratios — lower is generally safer
Alkermes plc carries a Debt/EBITDA ratio of 0.2x, which is very conservative (92% below the sector average of 3.1x). The company holds a net cash position — cash of $588M exceeds total debt of $70M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 20.7x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.05 | 0.31 | 0.36 | 0.37 | 0.38 | 0.27 | 0.24 | 0.23 | 0.23 |
| Debt / EBITDA | 0.25 | 0.25 | 0.17 | 0.76 | 5.29 | 2.36 | — | — | 61.63 | — | — |
| Net Debt / Equity | — | -0.28 | -0.15 | -0.07 | 0.08 | 0.07 | 0.13 | 0.08 | 0.01 | 0.07 | 0.08 |
| Net Debt / EBITDA | -1.84 | -1.84 | -0.48 | -0.17 | 1.21 | 0.45 | — | — | 2.77 | — | — |
| Debt / FCF | — | -995.32 | -0.53 | -0.24 | — | 1.08 | 3.38 | — | 0.42 | — | — |
| Interest Coverage | 20.69 | 20.69 | 18.63 | 17.98 | -0.47 | 8.71 | -12.98 | -12.90 | -6.42 | -12.32 | -14.01 |
Net cash position: cash ($588M) exceeds total debt ($70M)
Short-term solvency ratios and asset-utilisation metrics
Alkermes plc's current ratio of 2.06x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.70x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 2.86x to 2.06x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.06 | 2.06 | 3.04 | 2.86 | 2.27 | 2.25 | 2.53 | 2.46 | 2.89 | 3.32 | 4.30 |
| Quick Ratio | 1.70 | 1.70 | 2.65 | 2.50 | 1.91 | 1.93 | 2.25 | 2.20 | 2.63 | 3.00 | 4.01 |
| Cash Ratio | 1.08 | 1.08 | 1.62 | 1.49 | 1.22 | 1.14 | 1.45 | 1.37 | 1.59 | 1.49 | 2.35 |
| Asset Turnover | — | 0.59 | 0.76 | 0.78 | 0.57 | 0.58 | 0.53 | 0.65 | 0.60 | 0.50 | 0.43 |
| Inventory Turnover | 1.03 | 1.03 | 1.34 | 1.36 | 1.20 | 1.31 | 1.42 | 1.77 | 1.96 | 1.66 | 2.10 |
| Days Sales Outstanding | — | 82.61 | 91.28 | 73.11 | 97.47 | 101.55 | 101.74 | 82.75 | 100.22 | 94.38 | 93.54 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Alkermes plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 4.8% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 4.8% | 5.1% | 7.5% | 7.6% | — | — | — | — | — | — | — |
| FCF Yield | 0.0% | 0.0% | 8.3% | 7.5% | — | 1.9% | 1.3% | — | 0.7% | — | — |
| Buyback Yield | 0.0% | 0.0% | 4.1% | 0.6% | 0.4% | 0.4% | 0.2% | 0.3% | 0.4% | 0.2% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 4.1% | 0.6% | 0.4% | 0.4% | 0.2% | 0.3% | 0.4% | 0.2% | 0.2% |
| Shares Outstanding | — | $169M | $169M | $170M | $164M | $161M | $159M | $157M | $155M | $153M | $151M |
Compare ALKS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| ALKSYou | $5B | 21.0 | 15.9 | 9571.4 | 86.3% | 17.2% | 14.7% | 14.9% | 0.2 |
| UTHR | $22B | 18.1 | 12.9 | 21.1 | 87.9% | 46.9% | 19.7% | 21.1% | — |
| ZLAB | $21B | -12.0 | — | — | 58.6% | -49.9% | -22.6% | -42.8% | — |
| AMRN | $6B | -3.5 | — | — | 35.6% | -40.2% | -15.8% | -18.7% | — |
| ADMA | $4B | 19.2 | 25.1 | 33.7 | 51.5% | 32.6% | 81.6% | 37.7% | 0.6 |
| ARQT | $3B | -207.5 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
| LQDA | $3B | -18.7 | — | — | 58.0% | -866.6% | -209.4% | -500.7% | — |
| SLGL | $3B | -241.3 | — | — | 98.0% | -104.1% | -31.4% | -41.5% | — |
| MLYS | $2B | -8.0 | — | — | — | — | -82.2% | -107.3% | — |
| ARDX | $2B | -25.2 | — | — | 90.3% | -10.1% | -36.2% | -10.8% | — |
| TBPH | $925M | -15.9 | — | — | 100.0% | -72.9% | -29.0% | -17.2% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 30 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how ALKS stacks up against sector leader United Therapeutics Corporation.
Start ComparisonAlkermes plc's current P/E ratio is 21.0x. The historical average is 42.7x. This places it at the 71th percentile of its historical range.
Alkermes plc's current EV/EBITDA is 15.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.2x.
Alkermes plc's return on equity (ROE) is 14.7%. The historical average is -17.5%.
Based on historical data, Alkermes plc is trading at a P/E of 21.0x. This is at the 71th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Alkermes plc has 86.3% gross margin and 17.2% operating margin. Operating margin between 10-20% is typical for established companies.
Alkermes plc's Debt/EBITDA ratio is 0.2x, indicating low leverage. A ratio below 2x is generally considered financially healthy.